Stock Code: 301033 Stock Abbreviation: Medprin Listing Venue: Shenzhen Stock Exchange
[Chart: Medprin Logo]
Guangzhou Medprin Regenerative Medical Technologies Co., Ltd. Summary of the Report (Draft) (Revised) on Issuance of Shares and Payment of Cash to Purchase Assets and Raise Supporting Funds and Related Party Transactions
| Item | Name |
|---|---|
| Counterparties for asset purchase | Guangzhou Zexin Medical Technology Co., Ltd. |
| Guangzhou Yichuangxiang Investment Partnership (Limited Partnership) | |
| Guangzhou Huangpu Xian-Dao Medical Venture Capital Fund Partnership (Limited Partnership) | |
| Guangdong Jieke Achievement Transformation Venture Capital Fund Partnership (Limited Partnership) | |
| Hu Ganwei | |
| Guangzhou Fuheng Investment Co., Ltd. | |
| Yuan Ziyang | |
| Guangzhou Industrial Investment Bio-medicine and Health Special Mother Fund Partnership (Limited Partnership) | |
| Guangzhou Industrial Investment Productivity Venture Capital Partnership (Limited Partnership) | |
| Guangzhou Youjiu Equity Investment Center (Limited Partnership) | |
| Subscriber for supporting funds | Guangzhou Yijie Medical Investment Co., Ltd. |
Independent Financial Advisor Huatai United Securities Co., Ltd.
Signing Date: June 2026 [blank]
Statement
The terms or abbreviations used in this section have the same meanings as those defined in the "Definitions" section of this report summary.
I. Statement of the Listed Company
The Company and all its directors and senior management guarantee that the information disclosed by the Company is timely and fair, and that the contents of this report summary are true, accurate, and complete, without false records, misleading statements, or major omissions. They guarantee the truthfulness and reasonableness of the relevant data cited in this report summary and assume corresponding legal liability for the truthfulness, accuracy, and completeness of the information provided.
If the information disclosed or provided in this transaction is suspected of containing false records, misleading statements, or major omissions, and is subject to case investigation by judicial authorities or the China Securities Regulatory Commission (CSRC), the parties involved shall not transfer the shares held in the listed company until the investigation conclusion is formed. They shall submit a written application for suspension of transfer and their stock account to the board of directors of the listed company within two trading days of receiving the notice of investigation, and the board of directors shall apply for locking on their behalf to the stock exchange and the securities registration and clearing institution. If the application for locking is not submitted within two trading days, the board of directors is authorized to verify and directly report the identity and account information of the individual or entity to the stock exchange and the securities registration and clearing institution to apply for locking. If the board of directors fails to report the information, the stock exchange and the securities registration and clearing institution are authorized to directly lock the relevant shares. If the investigation concludes that there are illegal or non-compliant circumstances, the individual or entity promises that the locked shares will be voluntarily used for investor compensation arrangements.
Any decision or opinion made by the CSRC or the Shenzhen Stock Exchange regarding this transaction does not represent a substantive judgment or guarantee of the value of the Company's shares or investor returns.
In accordance with the Securities Law and other relevant laws and regulations, after the completion of this transaction, the Company is solely responsible for changes in its operations and earnings, and investors are solely responsible for investment risks arising from such changes. When evaluating this transaction, investors should carefully consider the risk factors disclosed in this report summary in addition to the contents of this report summary and other documents disclosed simultaneously. If investors have any questions about this report summary, they should consult their stockbroker, lawyer, accountant, or other professional advisor.